Skip to content
Clinical Trials – home
Universitair Medisch Centrum Groningen
Sponsor

Universitair Medisch Centrum Groningen

The Netherlands Hanzeplein 1, 9713 GZ Groningen, The Netherlands

About the sponsor

Research activity is strongly centered on chronic kidney disease, albuminuria, autosomal dominant polycystic kidney disease, and kidney failure, with additional work in kidney transplantation and lung transplantation.

  • Renal function preservation
  • Proteinuria and albuminuria
  • Polycystic kidney disease
  • Transplant immunology

The portfolio also includes studies in primary aldosteronism and methods related to glomerular filtration rate assessment.

About Specializations

Universitair Medisch Centrum Groningen runs clinical trials in conditions such as Chronic kidney disease, Squamous cell carcinoma of head and neck, Inflammatory bowel disease, Giant cell arteritis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

62 clinical trials

Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitair Medisch Centrum Groningen

A study to compare the effects of BI 690517 and spironolactone on kidney function in patients with heart failure, cardiovascular disease, or chronic kidney disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Universitair Medisch Centrum Groningen

A study testing finerenone compared to placebo in patients with chronic kidney disease who are not taking renin-angiotensin-system inhibitors

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Universitair Medisch Centrum Groningen

Study Using Fluorescent Adalimumab and Risankizumab to See How These Drugs Work in Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Universitair Medisch Centrum Groningen

Evaluating Somatostatin Receptor 2 Expression Using [68Ga]Ga-DOTA-TOC PET/CT Imaging in Patients with Epstein-Barr Virus Associated Nasopharyngeal Carcinoma

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitair Medisch Centrum Groningen

Study on the Effects of Mepolizumab on Nasal Health and Immune Response in Patients with Eosinophilic Granulomatosis with Polyangiitis (eGPA)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mepolizumab
  • Sponsor:Universitair Medisch Centrum Groningen

Study on [68Ga]FAPI-46 to Detect Lung Fibroblast Activity in COVID-19 Patients with Long-Term Symptoms

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Study on the Use of FAPI-PET/CT and FDG-PET/CT Scans for Detecting Active Fibroblasts and Inflammation in Patients with Acute Phase Peyronie's Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Study on CD8 PET Imaging for Patients with Metastatic Solid Tumors Using 89Zr-Df-crefmirlimab, Nivolumab, and Cetrelimab

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Universitair Medisch Centrum Groningen

PET/CT Imaging Study for Patients with Giant Cell Arteritis or Rheumatoid Arthritis Using Zirconium (89Zr) Crefmirlimab Berdoxam

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zirconium (89ZR) crefmirlimab berdoxam
  • Sponsor:Universitair Medisch Centrum Groningen

Study on Leflunomide for Preventing Relapses in Patients with Polymyalgia Rheumatica During Steroid Reduction

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Leflunomide
  • Sponsor:Universitair Medisch Centrum Groningen

Study of Pembrolizumab for Patients with Mismatch Repair Deficient Uterine Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Universitair Medisch Centrum Groningen

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.